ClinicalTrials.gg
Status unknownNCT04668976Updated Dec 21, 2020

A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma

A Phase 2 interventional study of Medtronic pump and Codman catheter and Floxuridine (FUDR) in Colorectal Cancer and Cholangiocarcinoma, sponsored by Benaroya Research Institute. Status unknown at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-12-21.

Sponsored by Benaroya Research Institute · Phase 2, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Dec 2020), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies testing floxuridine in Colorectal Neoplasms — 5 open to participants now, 6 under way, 3 of them phase 3. Floxuridine · Colorectal Neoplasms.

Planned enrollment
9th of 25
100 · median 49
Started
2020
with 1 other
Phase 2
14 of 27
1 open now
Registered
22nd of 27
by date
Lead sponsor
1 of 27
Benaroya Research Institute

Among the 27 studies testing floxuridine in Colorectal Neoplasms, this one is the 9th largest by planned enrollment of the 25 interventional ones that give a count, is one of 2 that started in 2020, is one of 14 in phase 2, and was the 22nd registered.

Colorectal Neoplasms

6,555 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

5 of the 27 studies testing floxuridine in Colorectal Neoplasms are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About floxuridine

Floxuridine: first FDA approval 1970 (FUDR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing floxuridine in Colorectal Neoplasms, or all of them as a file.
02

Study summary

This study is being done to answer the following question:

Is the combination of the Medtronic pump and the Codman catheter device a safe alternative to the C3000 Codman pump for delivering chemotherapy directly into the liver of patients with metastatic colorectal cancer or cholangiocarcinoma?

Read the detailed description

Group 1 unresectable liver metastases from colorectal cancer

  • Patients will receive either FOLFIRI, FOLFOX, Irinotecan or Irinotecan/oxaliplatin (anti- EGFR agent may be added to any of the systemic treatments) on Days 1 and 15 of each cycle, however initiation with systemic chemotherapy will not take place until 4 weeks post-surgery for pump placement.

Group 2 resectable liver metastases from colorectal cancer - Patients will receive either FOLFIRI, FOLFOX, Irinotecan or Irinotecan/oxaliplatin on Days 1 and 15 of each cycle, however initiation with systemic chemotherapy will not take place until 4 weeks post-surgery for pump placement.

Group 3 unresectable cholangiocarcinoma

  • Patients will receive Gemcitabine (800 mg/m2 IV over 30 minutes) and Oxaliplatin (85 mg/ m2 IV over 120 minutes) or Gemcitabine (1000 mg/m2 IV over 30 minutes) alone on Days 1 and 15 of each cycle, however initiation with systemic chemotherapy will not take place until 4 weeks post-surgery for pump placement.
03

Conditions studied

  • Colorectal Cancer
  • Cholangiocarcinoma

Keywords

  • Medtronic Pump
  • Codman Catheter
  • Hepatic Arterial Infusion (HAI)
  • Floxuridine (FUDR)
  • Gemcitabine
  • Oxaliplatin
  • Irinotecan (CPT-11)
  • Fluorouracil
  • Leucovorin Calcium (Folinic Acid)
  • Dexamethasone
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. History of confirmed colorectal adenocarcinoma to the liver with no clinically or radiographically confirmed extrahepatic disease (or) Histologically confirmed cholangiocarcinoma (Clinical or radiographic evidence of metastatic disease that has been resected is allowed, provided there is no recurrence in that area prior to protocol consent)
  2. Confirmation of diagnosis must be performed at VMMC
  3. Participant may have completely resected hepatic metastases without current evidence of other metastatic disease
  4. Lab values ≤14 days prior to registration:

    ≥ 1.0(9)/L count ≥ 75 (9)/L Creatinine ≤1.8 mg/dL 0 to 2x reference value ALK PHOS 0 to \< 1.2 x reference value Tot Bili 0 to \< 1.2 x reference value

  5. Prior chemotherapy is acceptable if last dose of oxaliplatin or irinotecan is given ≥3 weeks prior to planned first dosing on this protocol. 5-FU or 5-FU leucovorin may be given ≥2 weeks prior to planned first dosing on this protocol. [Note: no chemotherapy to be given after resection of liver lesions prior to treatment on this study]
  6. Any investigation agent is acceptable if administered ≥3 months before planned first dose on this protocol
  7. \<=1
  8. Participants ≥18 years of age

Exclusion criteria

Exclusion Criteria:

  1. Prior radiation to the liver (prior radiation therapy to the pelvis is acceptable if competed at least 4 weeks prior to the planned first dose of treatment on protocol)
  2. Colorectal cancer that is BRAF mutant or defective in mismatch repair.
  3. Active infection, ascites, hepatic encephalopathy
  4. Female participants who are pregnant or lactating - or planning to become pregnant within 6 months after the end of the treatment (female participants of must have negative pregnancy test ≤72 hours before treatment start)
  5. If in the opinion of the treating investigator a participant has any serious medical problems which may preclude receiving this type of treatment
  6. Participants with current evidence of hepatitis A, B, C (i.e., active hepatitis)
  7. Participants with history or known presence of primary CNS tumors, seizures not well- controlled with standard medical therapy, or history of stroke will also be excluded
  8. Serious or non-healing active wound, ulcer, or bone fracture
  9. History of other , except:

    1. Malignancy treated with curative intent and with no known active disease present for ≥3 years prior to registration and felt to be at low risk for recurrence by the treating physician
    2. Adequately treated non-melanomatous skin cancer or lentigo malignant without evidence of disease
    3. Adequately treated cervical carcinoma in situ without evidence of disease
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Pump Therapy

    All patients will undergo surgery to have the Medtronic pump and Codman catheter placed appropriately before HAI therapy can begin.

    Device: Medtronic pump and Codman catheter · Drug: Floxuridine (FUDR) · Drug: Gemcitabine · Drug: Oxaliplatin · Drug: Irinotecan (CPT-11) · Drug: Fluorouracil · Drug: Anti-EGFR (Panitumumab or Cetuximab)

Interventions

06

What researchers measure

Primary outcomes

  1. Number of patients requiring stent replacements

    Time frame: 1 year

  2. Percent frequency liver toxicity

    Alkaline phosphatase percent toxicity, Serum bilirubin percent toxicity

    Time frame: 1 year

Secondary outcomes

  1. Overall survival

    Overall survival is defined as the time from treatment initiation till the day of death or last follow-up whichever occurs first.

    Time frame: 1 year

  2. Progression free survival

    Progression free survival is defined as the time from treatment initiation till the day of progression or death whichever occurs first. Patients that are alive without progression at the end of the study will be censored.

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
  • Virginia mason medical Center
    Seattle, Washington 98101, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2020 (actual). Primary completion is estimated for Dec 2023, 37 months after the start.

Of 499 non-industry phase 2 interventional studies under Colorectal Neoplasms, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 75. This study's planned 37 months is below that.

Counting every sponsor, half of 619 studies reached it within 49 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2020
First posted
Dec 16, 2020
StartActual
Nov 25, 2020
Primary completionEst.
Dec 2023
CompletionEst.
Dec 2024
Last update
Dec 21, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 21, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04668976
Lead sponsor
Benaroya Research Institute
Collaborators
Virginia Mason Hospital/Medical Center
Responsible party
Sponsor
First posted
Dec 16, 2020
Start date
Nov 25, 2020
Primary completion
Dec 2023 (estimated)
Completion
Dec 2024 (estimated)
Last update
Dec 21, 2020

Study contacts

Hagen Kennecke, MD
Contact
Hagen.Kennecke@virginiamason.org
206-223-6193
Hagen Kennecke, MD
principal investigator · Virginia mason medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Floxuridine · Gemcitabine · Oxaliplatin · Irinotecan · Fluorouracil · EGFR Antibody

Start the discussion